SpringWorks Therapeutics Inc (NAS:SWTX)
$ 36.12 -0.08 (-0.22%) Market Cap: 2.68 Bil Enterprise Value: 2.25 Bil PE Ratio: 0 PB Ratio: 4.71 GF Score: 40/100

SpringWorks Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript

Jun 12, 2023 / 06:20PM GMT
Release Date Price: $27.31 (+0.22%)
Corinne Jenkins
Goldman Sachs Group, Inc., Research Division - VP

All right. Well, thanks, everyone, for joining us here. And thanks especially to Saqib Islam, CEO; and Badreddin Edris, COO for SpringWorks Therapeutics.

Questions & Answers

Corinne Jenkins
Goldman Sachs Group, Inc., Research Division - VP

Maybe just to kick us off this morning. Could you just provide a brief overview of the company, with a particular focus on what you see as key value drivers over the next 12 to 24 months?

Saqib Islam
SpringWorks Therapeutics, Inc. - CEO & Director

Sure. Thanks, and thanks for having us once again at your conference, Corrinne. I think we are in a very fortunate position of having at least 2 very meaningful drivers over the next 12, 24 months where you'll start off with nirogacestat for desmoid tumors, where we have submitted our Phase III data, where we are looking to have an approval this year in a disease where there is no approved therapy.

Following that, we've got data in our next drug,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot